Levetiracetam for Parkinson’s psychosis with study partner support
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 85 years old and generally healthy enough to join study visits
- Have a study partner who can meet with you at least 2 hours per week and help with medication (if needed)
- Have Parkinson’s disease psychosis symptoms (hallucinations, delusions, or similar) that started after Parkinson’s began and have lasted or happened for at least 1 month
- Have these psychosis symptoms at least once per week during the 4 weeks before screening
- If you take medicine for these symptoms, you must be off it for at least 2 weeks before randomization, and your Parkinson’s medicines should be stable for 4 weeks
- Be able to get repeated MRI scans and follow pregnancy prevention rules during the study and briefly after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called AGB101 (levetiracetam) can reduce overactivity in the hippocampus, a brain area important for memory. It is for healthy older adults who do not have memory problems, to see if the drug can help keep the brain working well.
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
This Phase 2 study tests whether an added medication strategy can change brain targets linked to memory decline in people with Parkinson’s disease, including those with no memory problems or mild memory changes. It may help lower risk of developing dementia, but you must be able to safely do MRI scans and meet other health and medication rules.
This study compares two drugs, pimavanserin and quetiapine, to see which works better for hallucinations or delusions caused by Parkinson's disease. The goal is to help patients manage these symptoms more effectively.
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson Disease Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.